Active Ingredient(s):Pegcetacoplan FDA Approved: * May 14, 2021 Pharm Company: *APELLIS PHARMACEUTICALS INC Category:Genetic Disorders
Pegcetacoplan, sold under the brand name Empaveli among others, is a medication used to treat paroxysmal nocturnal hemoglobinuria (PNH).
The most common side effects include injection-site reactions, infections, diarrhea, abdominal pain, respiratory tract infection, viral infection, and fatigue.
Paroxysmal nocturnal hemoglobinuria is characterized by red blood cell destruction, a...
* May have multiple approval dates, manufacturers, or labelers.